{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:13:27Z","timestamp":1785795207547,"version":"3.56.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Guillain-Barr\u00e9 syndrome (GBS) is an immune-mediated acute peripheral neuropathy in which up to 20% patients remain unable to walk independently after 6 months of onset. This study aimed to develop a clinical prognostic model based on the modified Erasmus GBS Outcome Score (mEGOS) for predicting the prognosis of GBS patients at 6 months of onset.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The clinical data of 201 GBS patients were retrospectively analyzed. According to the GBS disability score (GBS-DS) at 6 months of onset, patients were divided into a good prognosis group (GBS-DS &amp;lt;3 points) and a poor prognosis group (GBS-DS\u22653 points). Univariate and multivariate analysis was used to screen out independent risk factors for poor prognosis, and a prediction model was accordingly constructed for GBS prognosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mEGOS score, serum albumin (ALB) and fasting plasma glucose (FPG) were independent risk factors for poor prognosis in patients with GBS, and the above risk factors were used to construct a prognostic model of mEGOS-I and a nomogram. The receiver operating characteristic (ROC) curve showed that the area under curve (AUC) of mEGOS-I at admission and at 7 days of admission to predict poor prognosis at 6 months of GBS onset was 0.891 and 0.916, respectively, with sensitivities of 82.7% and 82.6% and specificities of 86.5% and 86.6%, respectively. Decision curve analysis showed that the nomogram had a very high clinical benefit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>To our knowledge, this is the first report of the construction of a prognostic prediction model based on the mEGOS score, ALB, and FPG that can accurately and stably predict the prognosis of GBS patients at 6 months of onset.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1303243","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T07:17:10Z","timestamp":1701328630000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Construction and evaluation of a prognostic prediction model based on the mEGOS score for patients with Guillain-Barr\u00e9 syndrome"],"prefix":"10.3389","volume":"14","author":[{"given":"Gaojie","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yani","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruochen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barre syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat Rev Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrneurol.2016.172","article-title":"Guillain-Barre syndrome: a century of progress","volume":"12","author":"Goodfellow","year":"2016","journal-title":"Nat Rev Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","article-title":"Clinical features, pathogenesis, and treatment of Guillain-Barr\u00e9 syndrome","volume":"7","author":"van Doorn","year":"2008","journal-title":"Lancet Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1016\/j.lpm.2013.02.328","article-title":"Diagnosis, treatment and prognosis of Guillain-Barre syndrome (GBS)","volume":"42","author":"van Doorn","year":"2013","journal-title":"Presse Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/jnnp-2011-301882","article-title":"Outcome and its predictors in Guillain-Barre syndrome","volume":"83","author":"Rajabally","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/0883073819826225","article-title":"A novel treatment strategy for severe Guillain-Barre syndrome: zipper method","volume":"34","author":"Kesici","year":"2019","journal-title":"J Child Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","article-title":"clinical prognostic scoring system for Guillain-Barr\u00e9 syndrome","volume":"6","author":"van Koningsveld","year":"2007","journal-title":"Lancet Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1212\/WNL.0b013e3182104407","article-title":"Early recognition of poor prognosis in Guillain-Barre syndrome","volume":"76","author":"Walgaard","year":"2011","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/acn3.51627","article-title":"Validation and adjustment of modified Erasmus GBS outcome score in Bangladesh","volume":"9","author":"Papri","year":"2022","journal-title":"Ann Clin Transl Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1136\/jnnp-2020-323960","article-title":"Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barre syndrome","volume":"91","author":"Yamagishi","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12974-021-02301-0","article-title":"Autoantibody screening in Guillain-Barre syndrome","volume":"18","author":"Lleixa","year":"2021","journal-title":"J Neuroinflammation."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.24.20042200","article-title":"Serum neurofilament light chain predicts long-term prognosis in Guillain-Barre syndrome patients","author":"Martin-Aguilar","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B14","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/mus.20983","article-title":"Glial fibrillary acidic protein: a marker of axonal Guillain\u2013Barr\u00e8 syndrome and outcome","volume":"38","author":"Notturno","year":"2008","journal-title":"Muscle Nerve."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2147\/NDT.S162896","article-title":"Effect of serum inflammatory markers on the prognosis of adult and pediatric patients with Guillain-Barre syndrome","volume":"14","author":"Ethemoglu","year":"2018","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1097\/CCM.0000000000003635","article-title":"Dysglycemia and neurologic outcome in mechanically ventilated patients with guillain-barre syndrome","volume":"47","author":"Polito","year":"2019","journal-title":"Crit Care Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/00207454.2017.1418342","article-title":"The clinical significance of neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio in Guillain-Barre syndrome","volume":"128","author":"Huang","year":"2018","journal-title":"Int J Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain-Barre syndrome","volume":"27","author":"Asbury","year":"1990","journal-title":"Ann Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/jns.12320","article-title":"The utility of Guillain-Barre syndrome prognostic models in Malaysian patients","volume":"24","author":"Tan","year":"2019","journal-title":"J Peripher Nerv Syst."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1212\/WNL.0000000000013139","article-title":"Predicting outcome in Guillain-Barre syndrome: international validation of the modified erasmus GBS outcome score","volume":"98","author":"Doets","year":"2022","journal-title":"Neurology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41016-018-0122-y","article-title":"Prognostic factors of Guillain-Barr\u00e9 syndrome: a 111-case retrospective review","volume":"4","author":"Zhang","year":"2018","journal-title":"Chin Neurosurg J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1590\/0004-282X20160132","article-title":"Analysis of the albumin level, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio in Guillain-Barre syndrome","volume":"74","author":"Ozdemir","year":"2016","journal-title":"Arq Neuropsiquiatr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3109\/00207451003695690","article-title":"Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients","volume":"120","author":"Ghabaee","year":"2010","journal-title":"Int J Neurosci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00415-004-0348-9","article-title":"The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy","volume":"251","author":"Gilgun-Sherki","year":"2004","journal-title":"J Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/S1734-1140(13)71521-4","article-title":"Mechanisms and pharmacology of diabetic neuropathy \u2013 experimental and clinical studies","volume":"65","author":"Zychowska","year":"2013","journal-title":"Pharmacol Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12883-018-1211-4","article-title":"Guillain-Barre syndrome following bacterial meningitis: a case report and literature review","volume":"18","author":"Ding","year":"2018","journal-title":"BMC Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.2337\/diabetes.38.11.1456","article-title":"Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh epidemiology of diabetes complications study","volume":"38","author":"Maser","year":"1989","journal-title":"Diabetes."},{"key":"B28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/ene.12885","article-title":"Diabetes mellitus exacerbates the clinical and electrophysiological features of Guillain-Barre syndrome","volume":"23","author":"Bae","year":"2016","journal-title":"Eur J Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/jns.12206","article-title":"Diabetes mellitus may affect short-term outcome of Guillain-Barr\u00e9 syndrome","volume":"22","author":"Peric","year":"2017","journal-title":"J Peripheral Nervous System."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0145075","DOI":"10.1371\/journal.pone.0145075","article-title":"Fasting glucose levels correlate with disease severity of Guillain-Barre syndrome","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS ONE."},{"key":"B31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/01616412.2021.1965337","article-title":"Elevated blood and cerebrospinal fluid glucose levels affect the severity and short-term prognosis of Guillain-Barre syndrome","volume":"44","author":"Gong","year":"2022","journal-title":"Neurol Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.cmet.2013.05.001","article-title":"Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity","volume":"17","author":"Donath","year":"2013","journal-title":"Cell Metab."},{"key":"B33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3132\/dvdr.2007.025","article-title":"The endothelium and vascular inflammation in diabetes","volume":"4","author":"Hartge","year":"2007","journal-title":"Diab Vasc Dis Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.diabres.2010.11.008","article-title":"Altered nerve excitability in subclinical\/early diabetic neuropathy: evidence for early neurovascular process in diabetes mellitus?","volume":"91","author":"Bae","year":"2011","journal-title":"Diabetes Res Clin Pract."},{"key":"B35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.11604\/pamj.2017.26.86.11091","volume":"26","author":"Affes","year":"2017","journal-title":"Pan Afr Med J."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1303243\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T07:17:13Z","timestamp":1701328633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1303243\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":35,"alternative-id":["10.3389\/fneur.2023.1303243"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1303243","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]},"article-number":"1303243"}}